• Race Oncology appoints Associate Professor Erin Howden to scientific advisory board
• Howden has researched adverse effects of chemotherapy on cardiovascular fitness of cancer patients
• Appointment aims to bring Race Oncology’s new formulation of bisantrene to patients sooner

Special Report: Race oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients.

Clinical-stage biopharmaceutical company Race Oncology (ASX:RAC) has appointed Associate Professor Erin Howden, of the Baker Heart and Diabetes Institute in Melbourne, to its scientific advisory board. Read more here.